Literature DB >> 8513525

Cardiovascular stability with rapid intravenous infusion of ondansetron.

J S Heyman1, M L Young, R J Bagshaw, W J Levy, R T Geer, S J Aukburg, A F Joslyn, T J Conahan.   

Abstract

The acute cardiovascular effects of rapid iv administration of the antiemetic ondansetron, a selective serotonin (5-HT3) receptor antagonist were determined in a randomized, blinded, placebo-controlled study. Measurements of heart rate, blood pressure, oxygen saturation and respiratory rate were made preoperatively over a five-minute period which followed a two-minute infusion of the medication. Intraoperative and postoperative data were not collected. None of the variables recorded changed significantly during the infusion or in the observation period which followed. Within the limitations of this study, we detected no cardiovascular change in the five minutes between the end of the drug infusion and the induction of anaesthesia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8513525     DOI: 10.1007/BF03009516

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  21 in total

1.  The determination in plasma and pharmacokinetics of ondansetron.

Authors:  P V Colthup; J L Palmer
Journal:  Eur J Cancer Clin Oncol       Date:  1989

2.  Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors.

Authors:  A Butler; J M Hill; S J Ireland; C C Jordan; M B Tyers
Journal:  Br J Pharmacol       Date:  1988-06       Impact factor: 8.739

3.  Analysis of the heart rate effects of 5-hydroxytryptamine in the cat; mediation of tachycardia by 5-HT1-like receptors.

Authors:  P R Saxena; E J Mylecharane; J Heiligers
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-08       Impact factor: 3.000

4.  A 5-hydroxytryptamine receptor in human atrium.

Authors:  A J Kaumann; L Sanders; A M Brown; K J Murray; M J Brown
Journal:  Br J Pharmacol       Date:  1990-08       Impact factor: 8.739

5.  Inhibition of the 5-HT-induced cardiogenic hypertensive chemoreflex by the selective 5-HT3 receptor antagonist ICS 205-930.

Authors:  H Berthold; G Scholtysik; G Engel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-03       Impact factor: 3.000

6.  Ondansetron in the treatment of postoperative vomiting: a randomized, double-blind comparison with droperidol and metoclopramide.

Authors:  E Alon; S Himmelseher
Journal:  Anesth Analg       Date:  1992-10       Impact factor: 5.108

7.  Serotonin induced vasodilatation in the human forearm is antagonized by the selective 5-HT3 receptor antagonist ICS 205-930.

Authors:  G J Blauw; P van Brummelen; P A van Zwieten
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

8.  A comparison of cardiovascular and smooth muscle effects of 5-hydroxytryptamine and 5-carboxamidotryptamine, a selective agonist of 5-HT1 receptors.

Authors:  P R Saxena; A Lawang
Journal:  Arch Int Pharmacodyn Ther       Date:  1985-10

9.  MDL 72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors.

Authors:  J R Fozard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-05       Impact factor: 3.000

10.  5-Hydroxytryptamine3 receptors mediate tachycardia in conscious instrumented dogs.

Authors:  H Wilson; W J Coffman; M L Cohen
Journal:  J Pharmacol Exp Ther       Date:  1990-02       Impact factor: 4.030

View more
  2 in total

Review 1.  Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.

Authors:  M I Wilde; A Markham
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

Review 2.  Benefits and risks of newer treatments for chemotherapy-induced and postoperative nausea and vomiting.

Authors:  Anthony L Kovac
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.